WVE-006

PreclinicalSmall molecule

WWave Life Sciences Ltd.

WVE-006 is one of 15 small molecule programs targeting Alpha-1 Antitrypsin Deficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alpha-1 Antitrypsin DeficiencyRecruiting

Single Ascending DoseRecruiting

Alpha-1 Antitrypsin DeficiencyPreclinical

Recruiting

Single Ascending DosePreclinical

Recruiting

Competition

Competitive Landscape

15 competitors in Alpha-1 Antitrypsin Deficiency

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

1 2

SAR447537

Sanofi

Phase 2

1 3

Tylenol

KKenvue Brands

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ativan

BBausch Health Americas, Inc.

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

WVE-006

WWave Life Sciences Ltd.

Preclinical

1 9

Oxycodone/acetaminophen

MMontefiore Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Alpha-1 Antitrypsin Deficiency

NCT06405633

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

Completed·WWave Life Sciences Ltd.·Phase 1·NCT06186492·47 enrolled

Alpha-1 Antitrypsin Deficiency1 trial

A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)

Recruiting·WWave Life Sciences Ltd.·Preclinical·NCT06405633·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for WVE-006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WVE-006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WVE-006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wave Life Sciences Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWave Life Sciences Ltd.

WVE-006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Phase 11 trial

Alpha-1 Antitrypsin Deficiency1 trial

References

Drug Info

Quick Facts

Related News